Fully biodegradable nutraceutical packaging an industry first
An agreement signed between TricorBraun and BioBottles will give nutraceutical companies (and potentially pharmaceutical companies) in the US and Canada access to the industry’s first fully biodegradable packaging option.
American packaging designer and distributor TricorBraun have signed an exclusive agreement with BioBottlesTM to offer their biodegradable bottles to the nutraceutical industry, the first and only bottle of its kind for nutraceutical companies in the US and Canada.
In an effort to expand their current sustainable packaging offerings, the agreement will allow TricorBraun to exclusively offer BioBottles in the US and Canada. Made with proprietary technology, BioBottles offer nutraceutical companies and contract organisations an environmentally responsible alternative at a cost-effective price point, with scope to be utilised in pharmaceutical packaging needs.
“Sustainability matters to our customers and their consumers, and it matters to TricorBraun,” Mark O’Bryan, COO at TricorBraun, stated. “Our exclusive BioBottles agreement in another example of our focused efforts to offer comprehensive sustainable options for our customers. We are thrilled to partner with BioBottles to provide our customers with a solution that helps protect both their products and the planet.”
Manufacturered utilising Plastic IQTM technology, BioBottles and BioCapTM transforms HDPE and PP bottles, caps, scoops, and other items into a material that, when discarded, begins to degrade when exposed to UV, oxygen, and microorganisms. Fungi and bacteria are stimulated into treating the material as a food source and consume and fully degrade the packaging. BioBottles claims to leave behind no microplastics and convert into oxygen, carbon dioxide, and biomass, offering nutraceutical and pharmaceutical companies an industry-first, fully biodegradable packaging solution.
CEO and co-founder of BioBottles James Vanbrocklin commented on the partnership: “TricorBraun shares our dedication and commitment to providing sustainable packaging options for the benefit of the planet... We are excited to partner with a respected industry leader like TricorBraun to deliver this unique yet sustainable alternative for nutraceutical companies, and we look forward to working with TricorBraun to expand into new markets.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...